0

Lung Cancer Surgery Market: Current Analysis and Forecast (2021-2027)

Region:Global

Author(s):

Product Code:UMHE21274

Download Sample Report download
Buy the Full ReportStarting from $3500
Published on

June 2021

Total pages

98

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $3500

About the Report

About the Report

LUNG CANCER IS THE LETHAL LUNG TUMOUR PORTRAYED BY THE UNCONTROLLED GROWTH OF CELLS IN THE LUNG TISSUES. THE INTERPRETATION OF LUNG CANCER IS CONFIRMED BY BIOPSY, WHICH IS CARRIED OUT USING BRONCHOSCOPY OR CT GUIDANCE. LUNG CANCER SURGERY IS THE SURGICAL ABLATION OF CANCER TISSUE FROM THE LUNG. THE TYPE OF SURGERY DEPENDS UPON THE SIZE OF THE TUMOUR AND ITS POSITION WITHIN THE LUNG.

CANCER IS THE SECOND-LEADING CAUSE OF DEATH WORLDWIDE, ACCOUNTING FOR 10 MILLION DEATHS IN 2020. AS PER WHO, ABOUT 1 IN 6 DEATHS OCCUR DUE TO CANCER. 19.3 MILLION NEW CASES WERE REPORTED IN 2020, GLOBALLY. THE INCREASE IN CANCER INCIDENCE AT A GLOBAL SCALE ALSO INDICATES AN INCREASING TREND FOR THE PREVALENCE OF LUNG CANCERS WORLDWIDE. IN THIS SCENARIO CHARACTERIZED BY A FAVOURABLE FUNDING ENVIRONMENT AND EFFECTIVE TREATMENT OPTIONS, THE GROWING INCIDENCE AND PREVALENCE OF CANCER ARE EXPECTED TO INCREASE THE NUMBER OF PATIENTS OPTING FOR LUNG CANCER SURGERY IN THE COMING YEARS. THIS, IN TURN, IS EXPECTED TO DRIVE THE GROWTH OF THE MARKET IN THE COMING YEARS.

LUNG CANCER TREATMENTS ARE PRIMARILY DIVIDED INTO FOUR BROADER CATEGORIES; DIAGNOSIS/IMAGING, SURGERIES, PHARMACOLOGICAL ASSISTANCE, AND INDIRECT COSTS (LIKE TRANSPORTATION, CAREGIVER WAGES, LODGING, SECONDARY EFFECTS TREATMENTS, AND LOST WAGES/ INCOMES). THESE CATEGORIES INCUR SUBSTANTIAL SPENDING FROM GOVERNMENT/INSURANCE PROVIDERS AND ADDITIONAL COSTS PAID BY THE PATIENT ITSELF. THE HEFTY COSTS FOR TREATING LUNG CANCERS HAVE CREATED A SUBSTANTIAL BURDEN ON THE GOVERNMENTS GLOBALLY AND CANCER PATIENTS. CONSIDERING THESE HIGH COSTS, DESPITE THE PRESENCE OF A LARGE PATIENT POOL, A LIMITED NUMBER OF PATIENTS OPT FOR SURGICAL INTERVENTIONS TO TREAT THEIR CONDITION. THIS IS A MAJOR FACTOR RESTRAINING MARKET GROWTH.

BASED ON SURGERY TYPES, THE MARKET IS FRAGMENTED INTO THORACOTOMY AND MINIMALLY INVASIVE SURGERIES. THE THORACOTOMY SEGMENT GENERATED REVENUE OF USD XX BILLION IN 2020. HOWEVER, THE MINIMALLY INVASIVE SURGERIES SEGMENT IS EXPECTED TO GROW AT THE HIGHEST DURING THE FORECAST PERIOD OWING TO THE GROWING ADOPTION OF MINIMALLY INVASIVE TECHNIQUES, AND THE INCREASING TREND OF ROBOTIC SURGERIES. THORACOTOMY IS FURTHER BIFURCATED TO LOBECTOMY, SLEEVE RESECTION, SEGMENTECTOMY, AND PNEUMONECTOMY SURGERIES.

BASED ON THE DEVICE TYPE, THE MARKET IS FRAGMENTED INTO SURGICAL, MONITORING, AND ENDO-SURGICAL DEVICES. THE SURGICAL DEVICES SEGMENT GENERATED REVENUE OF USD XX BILLION IN 2020 AND IS ANTICIPATED TO REACH USD XX MILLION BY THE YEAR 2027F, GROWING AT A CAGR OF XX% OVER THE FORECAST PERIOD (2021-2027). THE RISING PREVALENCE & INCIDENCE OF LUNG CANCER ARE THE FACTORS DRIVING THE MARKET GROWTH.

FOR A BETTER UNDERSTANDING OF THE MARKET ADOPTION OF THE SINGLE PAIR ETHERNET MARKET, THE MARKET IS ANALYZED BASED ON ITS WORLDWIDE PENETRATION IN THE COUNTRIES SUCH AS NORTH AMERICA (UNITED STATES, CANADA, AND REST OF NORTH AMERICA), EUROPE (GERMANY, FRANCE, ITALY, SPAIN, UNITED KINGDOM AND REST OF EUROPE), ASIA-PACIFIC (CHINA, JAPAN, INDIA, AUSTRALIA, AND REST OF APAC), AND REST OF WORLD. NORTH AMERICA CONSTITUTES A MAJOR MARKET FOR LUNG CANCER SURGERY AND GENERATED REVENUE OF USD XX BILLION IN 2020 OWING TO THE IMPROVED HEALTHCARE INFRASTRUCTURE AND INCREASE IN HEALTHCARE SPENDING.

SOME OF THE MAJOR PLAYERS OPERATING IN THE MARKET INCLUDE GE HEALTHCARE, JOHNSON AND JOHNSON, OLYMPUS CORPORATION, SIEMENS HEALTHINEERS AG, ETHICON INC., MEDTRONIC PLC., KARL STORZ GMBH, ETC. SEVERAL M&A'S ALONG WITH PARTNERSHIPS HAVE BEEN UNDERTAKEN BY THESE PLAYERS TO BOOST THEIR PRESENCE IN DIFFERENT REGIONS.

Products


Companies

GE HEALTHCARE

JOHNSON AND JOHNSON

OLYMPUS CORPORATION

SIEMENS HEALTHINEERS AG

ETHICON INC.

MEDTRONIC PLC.

KARL STORZ GMBH

Table of Contents

Table of Contents

1 MARKET INTRODUCTION

1.1 MARKET DEFINITIONS

1.2 OBJECTIVE OF THE STUDY

1.3 LIMITATION

1.4 STAKE HOLDERS

1.5 CURRENCY USED IN REPORT

1.6 SCOPE OF THE GLOBAL LUNG CANCER SURGERY MARKET STUDY

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1 RESEARCH METHODOLOGY FOR THE GLOBAL LUNG CANCER SURGERY MARKET

2.1.1 MAIN OBJECTIVE OF THE GLOBAL LUNG CANCER SURGERY MARKET

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 TOP START-UPS UNDER LUNG CANCER SURGERY INDUSTRY

6 COVID-19 IMPACT

7 GLOBAL LUNG CANCER SURGERY MARKET REVENUE

8 MARKET INSIGHTS BY SURGERY

8.1 THORACOTOMY

8.1.1 LOBECTOMY

8.1.2 SLEEVE RESECTION

8.1.3 SEGMENTECTOMY

8.1.4 PNEUMONECTOMY

8.2 MINIMALLY INVASIVE SURGERY

9 MARKET INSIGHTS BY DEVICE

9.1 SURGICAL DEVICES

9.2 MONITORING DEVICES

9.3 ENDO-SURGICAL DEVICES

10 MARKET INSIGHTS BY REGION

10.1 NORTH AMERICA LUNG CANCER SURGERY MARKET

10.1.1 UNITED STATES

10.1.2 CANADA

10.1.3 REST OF NORTH AMERICA

10.2 EUROPE LUNG CANCER SURGERY MARKET

10.2.1 GERMANY

10.2.2 FRANCE

10.2.3 UNITED KINGDOM

10.2.4 SPAIN

10.2.5 ITALY

10.2.6 REST OF EUROPE

10.3 ASIA PACIFIC LUNG CANCER SURGERY MARKET

10.3.1 CHINA

10.3.2 JAPAN

10.3.3 INDIA

10.3.4 AUSTRALIA

10.3.5 REST OF ASIA PACIFIC

10.4 REST OF THE WORLD LUNG CANCER SURGERY MARKET

11 LUNG CANCER SURGERY MARKET DYNAMICS

11.1 MARKET DRIVERS

11.2 MARKET CHALLENGES

11.3 IMPACT ANALYSIS

12 LEGAL & REGULATORY FRAMEWORK

13 DEMAND AND SUPPLY SIDE ANALYSIS

14.1 DEMAND SIDE ANALYSIS

14.2 SUPPLY SIDE ANALYSIS

14.2.1 TOP PRODUCT LAUNCHES

14.2.2 TOP BUSINESS PARTNERSHIPS

14.2.3 TOP MERGER & ACQUISITIONS

14 VALUE CHAIN ANALYSIS

15 LUNG CANCER SURGERY MARKET OPPORTUNITIES

16 LUNG CANCER SURGERY MARKET TRENDS & INSIGHTS

17 COMPETITIVE SCENARIO

17.1 PORTER'S FIVE FORCES ANALYSIS

17.1.1 BARGAINING POWER OF SUPPLIER

17.1.2 BARGAINING POWER OF BUYER

17.1.3 INDUSTRY RIVALRY

17.1.4 AVAILABILITY OF SUBSTITUTE

17.1.5 THREAT OF NEW ENTRANTS

18 COMPANY PROFILED

18.1 MEDTRONIC PLC

18.2 ACCURACY INCORPORATED

18.3 GE HEALTHCARE

18.4 JOHNSON AND JOHNSON

18.5 OLYMPUS CORPORATION

18.6 SIEMENS HEALTHINEERS AG

18.7 ETHICON INC.

18.8 KARL STORZ GMBH

19 DISCLAIMER

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022